Loading...
XSTOSPRINT
Market cap10mUSD
Dec 23, Last price  
1.68SEK
1D
3.70%
1Q
30.23%
Jan 2017
-94.62%
IPO
-88.95%
Name

Sprint Bioscience AB

Chart & Performance

D1W1MN
XSTO:SPRINT chart
P/E
—
P/S
2.32
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
42.58%
Rev. gr., 5y
22.99%
Revenues
50m
+60,725.30%
2,367,9401,588,3382,371,0004,609,9267,726,61134,992,08223,967,00017,936,00033,541,00016,885,00035,114,00083,00050,485,000
Net income
-438k
L-99.27%
-1,376,930-3,545,289-4,387,000-11,463,623-15,500,1014,540,852-10,663,000-22,216,000-22,744,000-46,233,000-25,352,000-60,170,000-438,000
CFO
23m
P
-2,292,000-3,566,000-10,758,973833,5457,934,875-23,052,000-19,083,000-28,003,000-32,223,000-40,117,000-59,054,00022,871,000
Earnings
Feb 12, 2025

Profile

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.
URL
https://www.sprintbioscience.com/
IPO date
Nov 07, 2014
Employees
27
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
50,485
60,725.30%
83
-99.76%
35,114
107.96%
Cost of revenue
8,698
60,992
32,615
Unusual Expense (Income)
NOPBT
41,787
(60,909)
2,499
NOPBT Margin
82.77%
7.12%
Operating Taxes
269
Tax Rate
10.76%
NOPAT
41,787
(60,909)
2,230
Net income
(438)
-99.27%
(60,170)
137.34%
(25,352)
-45.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
2
17,903
88,803
BB yield
0.00%
-76.97%
-53.44%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(49,984)
(29,543)
(70,694)
Cash flow
Cash from operating activities
22,871
(59,054)
(40,117)
CAPEX
(2,454)
(2,707)
Cash from investing activities
(2,454)
(2,707)
Cash from financing activities
24
17,903
86,393
FCF
39,780
(60,291)
113
Balance
Cash
49,934
29,493
70,644
Long term investments
50
50
50
Excess cash
47,460
29,539
68,938
Stockholders' equity
(246,121)
(245,685)
(188,511)
Invested Capital
273,895
273,873
258,965
ROIC
15.26%
1.01%
ROCE
150.45%
3.55%
EV
Common stock shares outstanding
69,810
42,059
34,653
Price
1.74
214.65%
0.55
-88.47%
4.80
-37.57%
Market cap
121,469
422.25%
23,259
-86.00%
166,161
4.52%
EV
71,485
(6,284)
95,467
EBITDA
42,234
(60,291)
3,089
EV/EBITDA
1.69
0.10
30.91
Interest
269
Interest/NOPBT
10.76%